Effect of antibiotic therapy on the inflammatory responses during streptococcal pneumonia in emphysematous mice

EXCLI Journal

Volumn 8, Issue , 2009, Pages 50-57

  Inoue, Sumito ^a   Nakamura, Hidenori ^b   Shibata, Yoko ^a   Abe, Shuichi ^a   Takabatake, Noriaki ^a   Sata, Makoto ^c   Takeda, Hiroaki ^d   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d Yamagata Saisei Hospital   (Japan)

Author keywords

COPD; Cytokine; Respiratory infection; Respiratory quinolone

Indexed keywords

EID: 70349935401     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Almirall J, Boixeda R, Bolíbar I, Bassa J, Sauca G, Vidal J, Serra-Prat M, Balanzó X, GEMPAC Study Group. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. Respir Med 2007;101:2168-75.
2. Benton KA, VanCott JL, Briles DE. Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae. Infect Immun 1998;66:839-42.
3. Bouza E, Pintado V, Rivera S, Blázquez R, Muñoz P, Cercenado E, Loza E, Rodríguez-Créixems M, Moreno S, Spanish Pneumo-coccal Infection Study Network (G03/103). Nosocomial bloodstream infections caused by Streptococcus pneumoniae. Clin Microbiol Infect 2005;11:919-24.
4. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996;154: 959-67.
5. Cook PJ, Andrews JM, Wise R, Honey-bourne D, Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone anti-bacterial, in serum and lung compartments. J Antimicrob Chemother 1995;35:317-26.
6. DeAbate CA, Bettis R, Munk ZM, Fleming H, Munn NJ, Riffer E, Bagby B, Giguere G, Collins JJ. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther 1999;21: 172-88.
7. Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, Takahashi K, Nishimura K, Ishioka S, Aizawa H, Zaher C. COPD in Japan: the Nippon COPD Epide-miology study. Respirology 2004;9:458-65.
8. Hurd SS. International efforts directed at attacking the problem of COPD. Chest 2000;117:336S-8S.
9. Inoue S, Nakamura H, Otake K, Saito H, Terashita K, Sato J, Takeda H, Tomoike H. Impaired pulmonary inflammatory re-sponses are a prominent feature of streptococcal pneumonia in mice with experimental emphysema. Am J Respir Crit Care Med 2003;167:764-70.
10. Karlinsky JB, Snider GL. Animal models of emphysema. Am Rev Respir Dis 1978;117: 1109-33.
11. Lode H, Allewelt M, Balk S, De Roux A, Mauch H, Niederman M, Schmidt-Ioanas M. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007;35:143-9.
12. Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007;51: 3510-5.
13. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in spu-tum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116: 40-6.
14. Norrby SR. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment? J Antimicrob Chemother 1997;40(Suppl A):99-101.
15. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J, Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diag-nosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
16. Reinert RR, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P. An-timicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 2005;49:2903-13.
17. Saito H. Nakamura H, Kato S, Inoue S, Inage M, Ito M, Tomoike H. Percutaneous in vivo gene transfer to the peripheral lungs using plasmid-liposome complexes. Am J Physiol Lung Cell Mol Physiol 2000;279: L651-7.
18. Schumaker GL, Epstein SK. Managing acute respiratory failure during exacerba-tion of chronic obstructive pulmonary disease. Respir Care 2004;49:766-82.
19. Soler N, Torres A, Ewig S, Gonzalez J, Ce-lis R, El-Ebiary M, Hernandez C, Rodri-guez-Roisin R. Bronchial microbial patterns in severe exacerbations of chronic obstruc-tive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505.
20. Standiford TJ, Wilkowski JM, Sisson TH, Hattori N, Mehrad B, Bucknell KA, Moore TA. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative pneumonia. Hum Gene Ther 1999;10:899-909.
21. Suzuki K, Fujisawa T, Nakashima M, Hamasaki R. Antimicrobial activities of tosufloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella branhamella catarrhalis isolated from otolaryngological infectious diseases. J Infect Chemother 2005;11:253-5.
22. Takashima K, Tateda K, Matsumoto T, Ito T, Iizawa Y, Nakao M, Yamaguchi K. Estab-lishment of a model of penicillin resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice. J Med Microbiol 1996;45:319-22.
23. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997;65:257-60.
24. Tateda K, Takashima K, Miyazaki H, Matsumoto T, Hatori T, Yamaguchi K. Non-compromised penicillin-resistant pneumo-coccal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother 1996;40:1520-5.
25. Tokairin Y, Shibata Y, Sata M, Abe S, Takabatake N, Igarashi A, Ishikawa T, Inoue S, Kubota I. Enhanced immediate inflammatory response to Streptococcus pneumoniae in the lungs of mice with pulmonary em-physema. Respirology 2008;13:324-32.
26. Wakebe H, Imada T, Yoneda H, Mukai F, Ohguro K, Ohmori K, Tamaoka H, Yabuuchi Y. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Antimicrob Agents Chemother 1994;38:2340-5.
27. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-303.